FDA Grants Breakthrough Therapy Designation to RP1 Plus Nivolumab in Advanced Melanoma
RP1 plus nivolumab received breakthrough therapy designation from the FDA for the treatment of patients with PD-1 inhibitor–exposed advanced melanoma.
RP1 plus nivolumab received breakthrough therapy designation from the FDA for the treatment of patients with PD-1 inhibitor–exposed advanced melanoma.
Sorry, your request to load the app is timing out. Please check your internet connection and refresh the page. If the issue continues, try in…
An abstract is unavailable.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier…
Sorry, your request to load the app is timing out. Please check your internet connection and refresh the page. If the issue continues, try in…
One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
We save and improve lives by empowering people to take a proactive approach to daily sun protection and the early detection and treatment of skin…
The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are…
The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest…
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…